Modulation of Skin Cancer by the Stimulator of Interferon Genes.

Max Oscherwitz, Victoria Jiminez, Hanna Terhaar, Nabiha Yusuf

Open access · goldAbstract readReview

In one paragraph

Review in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.2field-weighted citation impact, top 39% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Max OscherwitzHeersink School of Medicine, University of Alabama, Birmingham, AL 35294, USA.

Victoria JiminezHeersink School of Medicine, University of Alabama, Birmingham, AL 35294, USA.

Hanna TerhaarHeersink School of Medicine, University of Alabama, Birmingham, AL 35294, USA.

Nabiha YusufDepartment of Dermatology, University of Alabama, Birmingham, AL 35294, USA.ORCID 0000-0001-5730-0037

University of Alabama · USUniversity of Alabama at Birmingham · US

Funding

Mechanisms elicited by type I interferons in cutaneous photocarcinogenesisR01AR071157 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YUSUF, NABIHA · 2016 to 2020

$1.8M

NIAMS NIH HHS 1R01AR071157-01A1NIAMS NIH HHS R01 AR071157

6 · The paper itself

Abstract

Morbidity and mortality from skin cancer continue to rise domestically and globally, and melanoma and non-melanoma skin cancers are a topic of interest in the dermatology and oncology communities. In this review, we summarize the stimulator of interferon genes (STING) pathway, its specific role in the pathogenesis of DNA damage and skin cancer, and STING-specific therapies that may fight both melanoma and non-melanoma skin (NMSC) cancers. Furthermore, we discuss specific portions of the STING pathway that may be used in addition to previously used therapies to provide a synergistic effect in future oncology treatments and discuss the limitations of current STING-based therapies.

Indexed as

InterferonsMelanomaMembrane ProteinsSkin NeoplasmsAnimalsDNA DamageHumansSignal TransductionSTING ProteinInterferonsMembrane ProteinsSTING1 protein, humanSTING Proteinbasal cell carcinomaBCCimmunotherapyinterferonsmelanomaSCCskin cancersquamous cell carcinomaSTING

Identifiers

PMID37761934

DOI10.3390/genes14091794

PMCPMC10530941

OpenAlexW4386713211

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.